



EDITORIAL

Methods, models, mechanisms and metadata: Introducing the Nanotoxicology collection at F1000Research [version 1; peer review: not peer reviewed]

Iseult Lynch¹, Penny Nymark², Philip Doganis³, Mary Gulumian⁴⁻⁶, Tae-Hyun Yoon^{7,8}, Diego S.T. Martinez⁹, Antreas Afantitis¹⁰

¹School of Geography, Earth and Environmental Sciences, University of Birmingham, Birmingham, B15 2TT, UK

²Institute of Environmental Medicine, Karolinska Institutet, Nobels väg 13, Stockholm, 17 177, Sweden

³School of Chemical Engineering, National Technical University of Athens, Athens, 10682, Greece

⁴National Health Laboratory Services, 1 Modderfontein Rd, Sandringham, Johannesburg, 2192, South Africa

⁵Haematology and Molecular Medicine, University of the Witwatersrand, 1 Jan Smuts Ave, Johannesburg, 2000, South Africa

⁶Water Research Group, Unit for Environmental Sciences and Management Potchefstroom, North West University, Potchefstroom, South Africa

⁷Department of Chemistry, College of Natural Sciences, Hanyang University, Seoul, 04763, South Korea

⁸Institute of Next Generation Material Design, Hanyang University, Seoul, 04763, South Korea

⁹Brazilian Nanotechnology National Laboratory (LNNano), Brazilian Center for Research in Energy and Materials (CNPEM), Campinas,, Sao Paulo, CEP 13083-970, Brazil

¹⁰Nanoinformatics department, NovaMechanics Ltd, Nicosia, Cyprus

V1 First published: 24 Nov 2021, 10:1196
<https://doi.org/10.12688/f1000research.75113.1>
Latest published: 24 Nov 2021, 10:1196
<https://doi.org/10.12688/f1000research.75113.1>

Abstract

Nanotoxicology is a relatively new field of research concerning the study and application of nanomaterials to evaluate the potential for harmful effects in parallel with the development of applications. Nanotoxicology as a field spans materials synthesis and characterisation, assessment of fate and behaviour, exposure science, toxicology / ecotoxicology, molecular biology and toxicogenomics, epidemiology, safe and sustainable by design approaches, and chemoinformatics and nanoinformatics, thus requiring scientists to work collaboratively, often outside their core expertise area. This interdisciplinarity can lead to challenges in terms of interpretation and reporting, and calls for a platform for sharing of best-practice in nanotoxicology research. The F1000Research Nanotoxicology collection, introduced via this editorial, will provide a place to share accumulated best practice, via original research reports including no-effects studies, protocols and methods papers, software reports and living systematic reviews, which can be updated as new knowledge emerges or as the domain of applicability of the method, model or software is expanded. This editorial introduces the Nanotoxicology Collection in *F1000Research*. The aim of the collection is to provide an open access platform for nanotoxicology researchers, to support an

Not Peer Reviewed

This article is an Editorial and has not been subject to external peer review.

Any comments on the article can be found at the end of the article.

improved culture of **data sharing** and documentation of evolving protocols, biological and computational models, software tools and datasets, that can be applied and built upon to develop predictive models and move towards *in silico* nanotoxicology and nanoinformatics. Submissions will be assessed for fit to the collection and subjected to the F1000Research open peer review process.

Keywords

Nanomaterials, nanosafety, exposure, toxicity, risk assessment, mode of action, toxicogenomics, bio-nano interface, nanoinformatics, FAIR data, standardisation, regulation, green and sustainable nanomaterials, safe-by-design, environmental fate and behaviour



This article is included in the **Nanotoxicology** collection.

Corresponding author: Iseult Lynch (i.lynch@bham.ac.uk)

Author roles: **Lynch I:** Conceptualization, Writing – Original Draft Preparation; **Nymark P:** Conceptualization, Writing – Review & Editing; **Doganis P:** Conceptualization, Writing – Review & Editing; **Gulumian M:** Conceptualization, Writing – Review & Editing; **Yoon TH:** Conceptualization, Writing – Review & Editing; **Martinez DST:** Conceptualization, Writing – Review & Editing; **Afantitis A:** Conceptualization, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This project was supported by the University of Birmingham.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Lynch I *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Lynch I, Nymark P, Doganis P *et al.* **Methods, models, mechanisms and metadata: Introducing the Nanotoxicology collection at F1000Research [version 1; peer review: not peer reviewed]** F1000Research 2021, 10:1196 <https://doi.org/10.12688/f1000research.75113.1>

First published: 24 Nov 2021, 10:1196 <https://doi.org/10.12688/f1000research.75113.1>

Introduction

A key challenge in science currently is the push for novelty and impact, which may be at the expense of reproducibility and repeatability in highly competitive areas, although recent literature suggests that the narrative of science in crisis is not supported by evidence¹. Using a qualitative analysis approach, Nelsen *et al.* identified that reproducibility discussions centred on the incentive structure of science, the transparency of methods and data, and the need to reform academic publishing, in addition to discussions focused on (quality/purity of) reagents, on statistical methods, and on the heterogeneity of the natural world². Supporting researchers in documenting the latter three aspects, and in enhancing the transparency of methods and data, are core missions of F1000Research, with its focus on open access publication, transparent and open peer-review, the versioning of papers as new data emerges, and the range of article types offered, including descriptions of *case studies, datasets, genomes, methods, protocols and software tools, as well as opinion articles, reviews, systematic and living systematic reviews and original research articles*. This documentation of the current state of science is vital as so much knowledge is implicit, passed from researcher to researcher within lab groups, and is often not documented or fully captured in the written protocols and method descriptions in publications. F1000Research offers a platform to document this information in a fully citable way!

In the nanotoxicology arena, as indeed in all branches of toxicology, the need for novelty as a route to publication has led to a clear bias in the published literature towards effects studies, with negative or no-effect studies being much harder to publish due to a perceived lack of novel insights or new modes of action³. Thus, a key goal of the F1000Research Nanotoxicology collection is to provide a home for well-designed, well-performed and well-documented studies at realistic concentrations and exposure conditions where low or no-effects are observed, in order to re-balance the literature and support development of predictive models based on balanced datasets. Additionally, low dose studies will allow new insights into the repair and recovery mechanisms that organisms induce in response to exposures, which are overwhelmed at higher exposures, including elucidation of normal housekeeping gene and protein expression, versus induction of repair mechanism such as anti-oxidants, DNA repair pathways, cell cycle arrest and protein clearance mechanisms, which have not yet been studied in depth for nanomaterials^{4,5}. Correlations between nanomaterials properties and biological impact, which are the foundations of toxicology and required for risk assessment, including modelling approaches are welcomed, as these also provide the basis for design of safer greener and more sustainable nanomaterials and products that are safe by design. Progress towards single cell-level evaluations of accumulation of nanomaterials and analysis of heterogeneity of responses is also an important emerging direction⁶. Mixture toxicity studies with nanomaterials and co-pollutants, including understanding the role of molecular interactions with the acquired biomolecule corona⁷, are very welcome also, as the nanotoxicology community is providing leadership in this emerging topic.

Back to basics: documenting the lessons learned and the weight of evidence

A common challenge in the toxicology and nanotoxicology arena is that acquired knowledge gets “lost” over time, and ends up being “re-discovered” later – examples of this include the potential for interference from nanomaterials with colorimetric assays⁸ and resulting in indirect toxicity due to binding of medium components (proteins⁹, micronutrients¹⁰ or released cytokines¹¹), which was very topical 15 years ago, but is rarely mentioned now despite still being an important issue, although it has recently been highlighted in the context of high-throughput screening of nanomaterials¹². Similarly, leaching of fluorescent labels from particles and the consequent risks of mis-quantification of nanomaterial uptake in organisms and cells was very topical a decade ago in nanosafety research^{13,14}, and is only recently being rediscovered in the microplastics and nanoscale plastics field¹⁵, along with renewed exploration of the impacts of preservatives in commercial nanoplastic particle dispersions¹⁶. Indeed, nanotoxicology itself has learned a huge amount from the particle toxicology community; for example knowledge about protein coronas dating back to early asbestos-studies^{17,18} was rediscovered within the field of nanotoxicology^{19–21}. Thus, a key goal of the F1000Research Nanotoxicology collection is to bring together this “community knowledge” in a single location to provide a set of key issues to consider for contiguous fields and for those newly entering the arena of materials safety assessment, be they legacy nanomaterials, micro or nanoplastics, or emerging advanced 2D materials and composite materials. Publication of *protocols* and standard operating procedures, guidance on best practice and checklists of reporting criteria are all examples of what we encourage submission of to build up this milestone collection.

Standardised and non-standardised test organisms and classical versus mechanistic toxicity assessment

A recurring debate in toxicology and nanotoxicology has been the need for standardisation of materials, methods, end-points and organisms to allow comparability of results versus the potential limitations of only using standardised organisms in terms of missing impacts in other species or at ecosystem level and the lack of mechanistic insights that can be gained from standard apical end-point tests^{22,23}. Many of the standardised organisms used in toxicity testing and the accompanying test methods were developed for soluble or non-particulate chemicals, and as such significant work has been done over the last two decades to evaluate the suitability of the existing tests for use with nanomaterials (applicable also to micro- and nano-scale plastic particles)^{24–26}. In parallel, the growing understanding of chemical versus physical or particle effects from nanomaterials, and the push towards alternatives to *in vivo* testing through development and utilisation of *in vitro* models such as air-liquid lung models^{27,28}, spheroid-type models and other 3D culture approaches^{29,30}, as well as the need for high throughput approaches and mechanistic insights to support grouping of nanomaterials and establishment of Adverse Outcome Pathways linking a molecular initiating event to a series of key events and an eventual

adverse outcome at organism, population or community levels^{31,32}, are all driving a push towards development of new models and new methods to support implementation of the 3R principles (Replacement, Reduction, and Refinement).

Development and validation of new methods and models is extremely time consuming, and although more flexible and slightly quicker validation approaches have been proposed to keep pace with the rapid technological development of new methods, validation is still essential for regulatory acceptance and adoption of Safe by Design and alternative methods and approaches^{33,34}. Thus, to support the steps within the control of the research community, including the pre-validation of methods through round-robins or interlaboratory comparisons (ILCs), the F1000Research collection will also provide a home for publication of results of nanomaterials ILCs and through our *methods papers* for complete documentation of the new *in vitro* or *in vivo* models and the accompanying *protocols* for application of the method. A key benefit of the F1000Research versioning approach is that as additional nanomaterials are assessed using the new method or protocol, or as comments from the research community on the protocol or method are received, this data can be added to the publication including additional authors where relevant (and with agreement of the original authors), through publication of a revised version, thus also facilitating streamlined extension of the domain of applicability of the method/protocol. The Data Availability Statement can also be updated with any new data in revised versions of papers. A similar process is also envisaged for computational models and software tools as discussed below. For the existing standardised model organisms, much of the literature on their underpinning biology, which is needed to enable interpretation of toxicological and ecotoxicological effects and outcomes, was published prior to the discovery of nanomaterials, and as such in-depth reviews of key biological pathways and processes that might be affected, either chemically or physically, by nanomaterials are also welcome as part of a set of reference publications on nanotoxicology, focussing on specific organisms or groups of related organisms.

FAIRification of datasets and documentation of models: the importance of agreed metadata

Nanoinformatics, while developing rapidly, is still a long way off the robustness of chemoinformatics approaches for small molecules, where huge easily accessible databases such as ChEMBL and others are well-established and data downloads can be automated and harmonised to meet the needs of modellers easily³⁵. This is the ultimate goal for nanotoxicology data also to drive the nanoinformatics wave, and the F1000Research collection will support this through publication of *software articles* describing models, *data* papers to document the

datasets underpinning original articles and nanoinformatics papers, and through the aforementioned versioning approach which will allow tools and models to be easily updated as their domains of applicability are extended. An emerging area of interest is also the building of predictive models for nanomaterials (eco)toxicology^{36,37}, including application of deep learning approaches³⁸ and integration of individual models into linked predictive models for risk assessment. While not yet applied to nanomaterials, comparison of model performance and establishment of consensus models is welcomed, and development of community standards around nanotoxicology metadata³⁹ to describe experimental and computational data from nanotoxicology, including through development of nanotoxicology-specific FAIR (Findable, Accessible, Interoperable and Re-usable) tools⁴⁰ and metrics⁴¹ and nanotoxicity-specific databases linked to purpose built databases for omics data, exposure data etc. are welcome. Considerations of how to increase the re-usability of computational models is also an emerging topic that the F1000Research Nanotoxicology collection will play a key role in driving forward. While it's too early to call it FAIRification of computational models, case studies on specific models and how they can be progressed through regulatory (e.g., OECD, ECVAM) validation processes and the role of documentation (e.g., of the underpinning hypotheses and datasets via the Quantitative Structure-Activity relationship (QSAR) model report forms, and the accompanying QSAR Prediction report form (QPAR)) in driving validation of such predictive models are topics that the Nanotoxicology collection will explore.

Conclusion

The F1000Research Nanotoxicology Collection offers researchers the opportunity to describe and fully document our models (biological and computational), methods (assays and protocols), mechanisms of action of nanomaterials including repair mechanisms and no-effect studies, datasets, best practice checklists, reporting guidelines and more, with full open access, transparent peer review and versioning to allow updating and extension of domains of applicability as new data become available. In the spirit of interdisciplinarity, the Nanotoxicology Collection will be looking to collaborate and interact with existing F1000Research gateways, such as [NC3Rs](#) and [Chemical Information Science](#), to accelerate research in these intersectional spaces. We look forward to receiving your nanotoxicology publications!

Acknowledgements

The F1000Research Nanotoxicology Collection was initiated by, and is technically supported by, Publishing Executive Jack Brook, to whom the authors express sincere thanks for the support to establish and launch the collection.

References

1. Fanelli D: **Opinion: Is science really facing a reproducibility crisis, and do we need it to?** *Proc Natl Acad Sci U S A*. 2018; **115**(11): 2628–2631. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Nelson NC, Ichikawa K, Chung J, et al.: **Mapping the discursive dimensions of the reproducibility crisis: A mixed methods analysis.** *PLoS One*. 2021; **16**(7): e0254090. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Lynch I, Klaper R: **Telling the important stories of “no adverse effect”**

- nanomaterials data.** *Environ Sci: Nano.* 2021; **8**: 1496–1499.
[Publisher Full Text](#)
4. Carriere M, Sauvaigo S, Douki T, et al.: **Impact of nanoparticles on DNA repair processes: current knowledge and working hypotheses.** *Mutagenesis.* 2017; **32**(1): 203–213.
[PubMed Abstract](#) | [Publisher Full Text](#)
 5. Quevedo AC, Lynch I, Valsami-Jones E: **Cellular repair mechanisms triggered by exposure to silver nanoparticles and ionic silver in embryonic zebrafish cells.** *Environ Sci: Nano.* 2021; **8**(9): 2507–2522.
[Publisher Full Text](#)
 6. Ha MK, Chung KH, Yoon TH: **Heterogeneity in Biodistribution and Cytotoxicity of Silver Nanoparticles in Pulmonary Adenocarcinoma Human Cells.** *Nanomaterials (Basel).* 2019; **10**(1): 36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 7. Martinez DST, Da Silva GH, de Medeiros AMZ, et al.: **Effect of the Albumin Corona on the Toxicity of Combined Graphene Oxide and Cadmium to *Daphnia magna* and Integration of the Datasets into the NanoCommons Knowledge Base.** *Nanomaterials (Basel).* 2020; **10**(10): 1936.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 8. Wörle-Knirsch JM, Pulskamp K, Krug HF: **Oops They Did It Again! Carbon Nanotubes Hoax Scientists in Viability Assays.** *Nano Lett.* 2006; **6**(6): 1261–1268.
[PubMed Abstract](#) | [Publisher Full Text](#)
 9. Casey A, Davoren M, Herzog E, et al.: **Probing the interaction of single walled carbon nanotubes within cell culture medium as a precursor to toxicity testing.** *Carbon.* 2007; **45**(1): 34–40.
[Publisher Full Text](#)
 10. Guo L, Von Dem Bussche A, Buechner M, et al.: **Adsorption of essential micronutrients by carbon nanotubes and the implications for nanotoxicity testing.** *Small.* 2008; **4**(6): 721–727.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 11. Herzog E, Byrne HJ, Casey A, et al.: **SWCNT suppress inflammatory mediator responses in human lung epithelium *in vitro*.** *Toxicol Appl Pharmacol.* 2009; **234**(3): 378–390.
[PubMed Abstract](#) | [Publisher Full Text](#)
 12. Andraos C, Yu JJ, Gulumian M: **Interference: A Much-Neglected Aspect in High-Throughput Screening of Nanoparticles.** *Int J Toxicol.* 2020; **39**(5): 397–421.
[PubMed Abstract](#) | [Publisher Full Text](#)
 13. Salvati A, Aberg C, dos Santos T, et al.: **Experimental and theoretical comparison of intracellular import of polymeric nanoparticles and small molecules: toward models of uptake kinetics.** *Nanomedicine.* 2011; **7**(6): 818–826.
[PubMed Abstract](#) | [Publisher Full Text](#)
 14. Tenuta T, Monopoli MP, Kim J, et al.: **Elution of Labile Fluorescent Dye from Nanoparticles during Biological Use.** *PLoS One.* 2011; **6**(10): e25556.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 15. Catarino AI, Frutos A, Henry TB: **Use of fluorescent-labelled nanoplastics (NPs) to demonstrate NP absorption is inconclusive without adequate controls.** *Sci Total Environ.* 2019; **670**: 915–920.
[PubMed Abstract](#) | [Publisher Full Text](#)
 16. Pikuda O, Xu EG, Berk D, et al.: **Toxicity Assessments of Micro- and Nanoplastics Can Be Confounded by Preservatives in Commercial Formulations.** *Environ Sci Technol Lett.* 2019; **6**(1): 21–25.
[Publisher Full Text](#)
 17. Brown RC, Sara EA, Hoskins JA, et al.: **Factors affecting the interaction of asbestos fibres with mammalian cells: a study using cells in suspension.** *Ann Occup Hyg.* 1991; **35**(1): 25–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
 18. MacCorkle RA, Slattery SD, Nash DR, et al.: **Intracellular protein binding to asbestos induces aneuploidy in human lung fibroblasts.** *Cell Motil Cytoskeleton.* 2006; **63**(10): 646–657.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Walczyk D, Bombelli FB, Monopoli MP, et al.: **What the cell “sees” in bionanoscience.** *J Am Chem Soc.* 2010; **132**(16): 5761–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. Nel AE, Mädler L, Velegol D, et al.: **Understanding biophysicochemical interactions at the nano-bio interface.** *Nat Mater.* 2009; **8**(7): 543–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. Cedervall T, Lynch I, Lindman S, et al.: **Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles.** *Proc Natl Acad Sci U S A.* 2007; **104**(7): 2050–2055.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 22. Krug HF: **Nanosafety Research—Are We on the Right Track?** *Angew Chem Int Ed Engl.* 2014; **53**(46): 12304–12319.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. Stefaniak AB, Hackley VA, Roebben G, et al.: **Nanoscale reference materials for environmental, health and safety measurements: needs, gaps and opportunities.** *Nanotoxicology.* 2013; **7**(8): 1325–1337.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Petersen EJ, Diamond SA, Kennedy AJ, et al.: **Adapting OECD Aquatic Toxicity Tests for Use with Manufactured Nanomaterials: Key Issues and Consensus Recommendations.** *Environ Sci Technol.* 2015; **49**(16): 9532–9547.
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. Johari SA, Rasmussen K, Gulumian M, et al.: **Introducing a new standardized nanomaterial environmental toxicity screening testing procedure, ISO/TS 20787: aquatic toxicity assessment of manufactured nanomaterials in saltwater Lakes using *Artemia sp. nauplii*.** *Toxicol Mech Methods.* 2019; **29**(2): 95–109.
[PubMed Abstract](#) | [Publisher Full Text](#)
 26. Ellis LJA, Valsami-Jones E, Lynch I: **Exposure medium and particle ageing moderate the toxicological effects of nanomaterials to *Daphnia magna* over multiple generations: a case for standard test review?** *Environ Sci: Nano.* 2020; **7**(4): 1136–1149.
[Publisher Full Text](#)
 27. Braakhuis HM, He R, Vandebriel RJ, et al.: **An Air-liquid Interface Bronchial Epithelial Model for Realistic, Repeated Inhalation Exposure to Airborne Particles for Toxicity Testing.** *J Vis Exp.* 2020; (159).
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Klein SG, Serchi T, Hoffmann L, et al.: **An improved 3D tetra-culture system mimicking the cellular organisation at the alveolar barrier to study the potential toxic effects of particles on the lung.** *Part Fibre Toxicol.* 2013; **10**(1): 31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. Tchoryk A, Taresco V, Argent RH, et al.: **Penetration and Uptake of Nanoparticles in 3D Tumor Spheroids.** *Biotechnol Biochem.* 2019; **30**(5): 1371–1384.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Guggenheim EJ, Milani S, Röttgermann PJF, et al.: **Refining *in vitro* models for nanomaterial exposure to cells and tissues.** *NanoImpact.* 2018; **10**: 121–142.
[Publisher Full Text](#)
 31. Halappanavar S, Nymark P, Krug HF, et al.: **Non-Animal Strategies for Toxicity Assessment of Nanoscale Materials: Role of Adverse Outcome Pathways in the Selection of Endpoints.** *Small.* 2021; **17**(15): e2007628.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. Halappanavar S, Ede JD, Mahapatra I, et al.: **A methodology for developing key events to advance nanomaterial-relevant adverse outcome pathways to inform risk assessment.** *Nanotoxicology.* 2021; **15**(3): 289–310.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Nymark P, Bakker M, Dekkers S, et al.: **Toward Rigorous Materials Production: New Approach Methodologies Have Extensive Potential to Improve Current Safety Assessment Practices.** *Small.* 2020; **16**(6): e1904749.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Judson R, Kavlock R, Martin M, et al.: **Perspectives on validation of high-throughput assays supporting 21st century toxicity testing.** *ALTEX.* 2013; **30**(1): 51–66.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 35. Afantitis A, Melagraki G, Isigonis P, et al.: **NanoSolveIT Project: Driving nanoinformatics research to develop innovative and integrated tools for *in silico* nanosafety assessment.** *Comput Struct Biotechnol J.* 2020; **18**: 583–602.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Varsou DD, Ellis LJA, Afantitis A, et al.: **Ecotoxicological read-across models for predicting acute toxicity of freshly dispersed versus medium-aged NMs to *Daphnia magna*.** *Chemosphere.* 2021; **285**: 131452.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Papadiamantis AG, Jänes J, Voyiatzis E, et al.: **Predicting Cytotoxicity of Metal Oxide Nanoparticles Using Isalos Analytics Platform.** *Nanomaterials (Basel).* 2020; **10**(10): 2017.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 38. Karatzas P, Melagraki G, Ellis LJA, et al.: **Development of Deep Learning Models for Predicting the Effects of Exposure to Engineered Nanomaterials on *Daphnia magna*.** *Small.* 2020; **16**(36): e2001080.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Papadiamantis AG, Klaessig FC, Exner TE, et al.: **Metadata Stewardship in Nanosafety Research: Community-Driven Organisation of Metadata Schemas to Support FAIR Nanoscience Data.** *Nanomaterials (Basel).* 2020; **10**(10): 2033.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Jeliakova N, Apostolova MD, Andreoli C, et al.: **Towards FAIR nanosafety data.** *Nat Nanotechnol.* 2021; **16**(6): 644–654.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Ammar A, Bonaretti S, Winckers L, et al.: **A Semi-Automated Workflow for FAIR Maturity Indicators in the Life Sciences.** *Nanomaterials (Basel).* 2020; **10**(10): 2068.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research